131511-13-2

Basic information

• Product Name: N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL
• Synonyms: N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL
• CAS NO: 131511-13-2
• Molecular Formula: C₁₅H₂₁NO₂
• Molecular Weight: 247.33274
• Mol File: 131511-13-2.mol

Chemical Properties

• Boiling Point: 374.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• PKA: 9.66±0.20(Predicted)
• CAS DataBase Reference: N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL(131511-13-2)
• EPA Substance Registry System: N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL(131511-13-2)

Safety Data

• Hazardous Substances Data: 131511-13-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL is used as a reagent for its role in the synthesis of complex organic molecules, contributing to the development of new chemical entities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL is used as a key intermediate, playing a crucial part in the production of pharmaceutical compounds.
Used in Medicinal Chemistry:
N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL is utilized for its potential biological activities and pharmacological properties, being investigated for its applications in medicinal chemistry.
Used in Material Science:
This chemical compound is also applied in material science, where its unique structure and properties can contribute to the advancement of new materials.
Used in Agrochemical Research:
N-BENZYL-4-AMINOCYCLOHEXANONE ETHYLENE KETAL is employed in agrochemical research, potentially leading to the development of new agrochemicals for various applications in agriculture.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 3287-99-8 benzylamine hydrochloride 
• 100-46-9 benzylamine 
• 230287-23-7 N-(1,4-dioxaspiro[4.5]decyl-7-idene)benzylamine 

Downstream Products

• 198290-36-7 4-(N-benzyltrichloroacetamido)-1-cyclohexanone ethylene acetal 

Relevant articles and documents

A palladium/norbornene cooperative catalysis to access N-containing bridged scaffolds

A palladium/norbornene cooperative catalysis promoted annulation involving an ortho-C-H amination and intramolecular Heck cascade between aryl iodides and functionalized amination reagents is reported, thereby providing a highly convergent access to the u

3-(dimethylaminomethyl) cyclohex-4-alcohol derivative as well as preparation method and pharmaceutical application thereof

The invention belongs to the field of pharmacy, and relates to a 3-(dimethylaminomethyl) cyclohex-4-alcohol derivative with a general formula (I) or a salt thereof and a preparation method, and relates to an application of the compound in treatment of opioid receptor mediated diseases. The present invention provides a pharmaceutically acceptable solvate or hydrate of a compound of formula (I), and also provides a pharmaceutical composition comprising: a compound of formula (I) or a pharmaceutically acceptable salt, solvate or hydrate thereof; and a pharmaceutically acceptable carrier. The medicine prepared from the compound can be used for treating or improving diseases related to an opioid receptor; wherein the diseases can be selected from but not limited to pain, gastrointestinal diseases and depression.

Organocatalytic Enantioselective Conia-Ene-Type Carbocyclization of Ynamide Cyclohexanones: Regiodivergent Synthesis of Morphans and Normorphans

Described herein is an organocatalytic enantioselective desymmetrizing cycloisomerization of arylsulfonyl-protected ynamide cyclohexanones, representing the first metal-free asymmetric Conia-ene-type carbocyclization. This method allows the highly efficient and atom-economical construction of a range of valuable morphans with wide substrate scope and excellent enantioselectivity (up to 97 % ee). In addition, such a cycloisomerization of alkylsulfonyl-protected ynamide cyclohexanones can lead to the divergent synthesis of normorphans as the main products with high enantioselectivity (up to 90 % ee). Moreover, theoretical calculations are employed to elucidate the origins of regioselectivity and enantioselectivity.

Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

Synthesis of the tetracyclic ABCD ring systems of madangamines D-F

Synthesis of the tetracyclic cores of madangamines D-F was achieved, featuring a reductive radical process from an ethoxycarbonyldichloroacetamide to build the morphan nucleus, a Mitsunobu-type aminocyclization toward the common diazatricyclic intermediate, and ring-closing metathesis reactions for the macrocyclization step leading to the 13- to 15-membered rings.

HETEROCYCLIC PROTEIN KINASE INHIBITORS

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

NEW COMPOUNDS

Novel compounds of which the following is exemplary:

Small, non-peptide C5a receptor antagonists: Part 1

The optimisation of a series of amides for C5a receptor binding and functional activity, and physicochemical properties is described. The initial hit, 1 (IC50 1 μM), was discovered during high throughput screening, from which highly potent C5a receptor antagonists (e.g. 14, IC50 5 nM) were developed.

Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds

Substituted 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl and 5,6,7,8-tetrahydro-quinazolin-2-yl compounds, corresponding to formula I processes for the production thereof, pharmaceutical preparations containing these compounds the use thereof for the production of pharmaceutical preparations and related method of treating or inhibiting certain disorders or conditions, including pain.

New dihydropteridione derivatives, process for their manufacture and their use as medicament

Disclosed are new dihydropteridinones of the formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings provided herein, the isomers thereof, processes for preparing these dihydropteridinones and their use as pharmaceutical compositions.